TerminatedPhase 1NCT00933985
Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia
Studying Acute undifferentiated leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Richard AplencCOG Phase I Consortium
- Intervention
- dexrazoxane hydrochloride(drug)
- Enrollment
- 22 enrolled
- Eligibility
- 21 years · All sexes
- Timeline
- 2009 – 2013
Study locations (20)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Childrens Hospital of Orange County, Orange, California, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
- Indiana University Medical Center, Indianapolis, Indiana, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- C S Mott Children's Hospital, Ann Arbor, Michigan, United States
- University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Columbia University Medical Center, New York, New York, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Oregon Health and Science University, Portland, Oregon, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
- St. Jude Children's Research Hospital, Memphis, Tennessee, United States
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00933985 on ClinicalTrials.govOther trials for Acute undifferentiated leukemia
Additional recruiting or active studies for the same condition.